Impax Labs Inc (IPXL) 24.03 $IPXL
Impax Provides Update on Epinephrine Injection, USP Auto-Injector
PR Newswire - Tue Aug 30, 7:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today provided an update and additional information to patients, physicians and customers on its epinephrine injection, USP auto-injector, 0.15 mg and 0.3 mg., the authorized generic of Adrenaclick®.
IPXL: 24.03 (+0.09)
Impax Laboratories, Inc. Issues Voluntary, Nationwide Recall for One Lot of Lamotrigine Orally Disintegrating Tablet 200 mg Due to the Potential for 100 mg Blister Cards being Packaged in 200 mg Containers
PR Newswire - Fri Aug 26, 5:30PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company had issued a voluntary nationwide retail level recall on August 19, 2016 for one lot of Lamotrigine Orally Disintegrating Tablet (ODT) 200 mg. The Company is issuing this press release to provide further heightened awareness of this recall and to provide instructions to consumers, pharmacists, and wholesalers in possession of the affected product. Details related to the recalled product are set forth below.
IPXL: 24.03 (+0.09)
Look for Shares of Impax Laboratories to Potentially Pullback after Yesterday's 2.66% Rise
Comtex SmarTrend(R) - Mon Aug 22, 3:56PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $23.27 to a high of $24.29. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $23.59 on volume of 599,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IPXL: 24.03 (+0.09)
Impax Laboratories Set to Possibly Pullback After Yesterday's Rally of 2.66%
Comtex SmarTrend(R) - Mon Aug 22, 3:55PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $23.27 to a high of $24.29. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $23.59 on volume of 599,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IPXL: 24.03 (+0.09)
Upgrade Alert for Impax Laboratories (IPXL)
Comtex SmarTrend(R) - Tue Aug 16, 3:03AM CDT
Impax Laboratories (NASDAQ:IPXL) was upgraded from Market Perform to Outperform at Northland today. The stock closed yesterday at $22.97 on volume of 1.4 million shares, above average daily volume of 539,000. In the past 52 weeks, Impax Laboratories share prices have been bracketed by a low of $20.97 and a high of $52.10 and closed yesterday at $22.97, 10% above that low price. The 200-day and 50-day moving averages have moved 0.87% lower and 0.04% lower over the past week, respectively.
IPXL: 24.03 (+0.09)
Impax Laboratories Has Returned 23.0% Since SmarTrend Recommendation (IPXL)
Comtex SmarTrend(R) - Thu Aug 11, 1:35PM CDT
SmarTrend identified a Downtrend for Impax Laboratories (NASDAQ:IPXL) on June 21st, 2016 at $28.86. In approximately 2 months, Impax Laboratories has returned 22.97% as of today's recent price of $22.23.
IPXL: 24.03 (+0.09)
5 Low Price-to-Book Stocks That Can Prove Valuable
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 7:13AM CDT
The price-to-book ratio (P/B ratio), though underrated, is also an easy-to-use valuation tool for identifying low-priced stocks with high-growth prospects.
IPXL: 24.03 (+0.09), KEP: 25.87 (+0.11), NTT: 45.31 (+0.83), HZNP: 17.84 (-0.78), DF: 17.25 (+0.20)
Valeant, Endo and Monster Worldwide surge; Gap slackens
AP - Tue Aug 09, 4:37PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
IPXL: 24.03 (+0.09), ENDP: 19.82 (-0.41), VRX: 28.76 (-0.36), DAL: 37.17 (+0.35), MWW: 3.72 (+0.05), MPAA: 29.06 (+0.39), GPS: 23.92 (-0.63), SNI: 63.83 (+0.25), VRX.TO: 37.34 (-0.75)
Impax Laboratories Falls 23.19% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 09, 1:07PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $22.08 to a high of $25.05. Yesterday, the shares fell 23.2%, which took the trading range below the 3-day low of $30.44 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IPXL: 24.03 (+0.09)
After Yesterday's Decline of 23.19%, Impax Laboratories Offers Investors Better Value
Comtex SmarTrend(R) - Tue Aug 09, 1:06PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $22.08 to a high of $25.05. Yesterday, the shares fell 23.2%, which took the trading range below the 3-day low of $30.44 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IPXL: 24.03 (+0.09)
Zacks.com featured highlights: Dean Foods, Korea Electric Power, Impax Laboratories, Xerox and AerCap Holdings N.V.
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:30AM CDT
Zacks.com featured highlights: Dean Foods, Korea Electric Power, Impax Laboratories, Xerox and AerCap Holdings N.V.
IPXL: 24.03 (+0.09), AER: 40.57 (+0.43), KEP: 25.87 (+0.11), XRX: 9.89 (+0.02), DF: 17.25 (+0.20)
Impax Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported second quarter 2016 financial results for the quarter ended June 30, 2016.
IPXL: 24.03 (+0.09)
5 Stocks with Low Price-to-Cash-Flow Ratio to Buy Now
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 6:35AM CDT
Investment in stocks made on diligent value analysis is usually considered one of the best practices.
IPXL: 24.03 (+0.09), AER: 40.57 (+0.43), KEP: 25.87 (+0.11), XRX: 9.89 (+0.02), DF: 17.25 (+0.20)
Mylan (MYL) Q2 Earnings: Will the Stock Disappoint?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 3:15PM CDT
Mylan (MYL), which is set to report second-quarter 2016 results on Aug 9, delivered a positive earnings surprise of 1.33% last quarter.
IPXL: 24.03 (+0.09), INCY: 82.02 (+1.21), MYL: 39.97 (-1.95), IONS: 29.46 (-0.58)
Tessera (TSRA) Surpasses Q2 Earnings & Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 2:18PM CDT
Tessera's djusted earnings of 55 cents per share surpassed the Zacks Consensus Estimate by 7.8% or 4 cents. Revenues of $67 million beat the consensus mark of $65 million by 3.1%.
IPXL: 24.03 (+0.09), TSRA: 33.79 (+0.08), MEET: 5.90 (+0.03), MYL: 39.97 (-1.95)
Monster Worldwide (MWW) Q2 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:42AM CDT
Monster Worldwide, Inc. (MWW) is set to report second-quarter 2016 results on Aug 9.
IPXL: 24.03 (+0.09), LNKD: 192.80 (+0.07), MWW: 3.72 (+0.05), MYL: 39.97 (-1.95)
BioDelivery (BDSI) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 6:58AM CDT
Last quarter, BioDelivery's loss was in-line with expectations. Let's see how things are shaping up for the second quarter of 2016.
IPXL: 24.03 (+0.09), BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), INCY: 82.02 (+1.21)
Jazz (JAZZ) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 6:45AM CDT
Our proven model does not conclusively show that Jazz (JAZZ) is likely to beat earnings estimates this quarter.
IPXL: 24.03 (+0.09), ADHD: 4.77 (+0.03), JAZZ: 120.84 (-2.47), INCY: 82.02 (+1.21)
Immune Design (IMDZ): Stock to Disappoint on Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 5:23PM CDT
Immune Design Corp. (IMDZ) is scheduled to report second-quarter 2016 results after the market closes on Aug 9.
IPXL: 24.03 (+0.09), IMDZ: 7.07 (-0.04), MRK: 62.98 (+0.08)
Will Endo (ENDP) Surprise This Earnings Season Again?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 5:22PM CDT
Endo International (ENDP) is set to report second-quarter 2016 results on Aug 8. It posted a positive earnings surprise of 2.86% last quarter.
IPXL: 24.03 (+0.09), ENDP: 19.82 (-0.41), MYL: 39.97 (-1.95), IONS: 29.46 (-0.58)
Impax Provides Update on Epinephrine Injection, USP Auto-Injector
PR Newswire - Tue Aug 30, 7:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today provided an update and additional information to patients, physicians and customers on its epinephrine injection, USP auto-injector, 0.15 mg and 0.3 mg., the authorized generic of Adrenaclick®.
IPXL: 24.03 (+0.09)
Impax Laboratories, Inc. Issues Voluntary, Nationwide Recall for One Lot of Lamotrigine Orally Disintegrating Tablet 200 mg Due to the Potential for 100 mg Blister Cards being Packaged in 200 mg Containers
PR Newswire - Fri Aug 26, 5:30PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company had issued a voluntary nationwide retail level recall on August 19, 2016 for one lot of Lamotrigine Orally Disintegrating Tablet (ODT) 200 mg. The Company is issuing this press release to provide further heightened awareness of this recall and to provide instructions to consumers, pharmacists, and wholesalers in possession of the affected product. Details related to the recalled product are set forth below.
IPXL: 24.03 (+0.09)
Look for Shares of Impax Laboratories to Potentially Pullback after Yesterday's 2.66% Rise
Comtex SmarTrend(R) - Mon Aug 22, 3:56PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $23.27 to a high of $24.29. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $23.59 on volume of 599,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IPXL: 24.03 (+0.09)
Impax Laboratories Set to Possibly Pullback After Yesterday's Rally of 2.66%
Comtex SmarTrend(R) - Mon Aug 22, 3:55PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $23.27 to a high of $24.29. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $23.59 on volume of 599,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IPXL: 24.03 (+0.09)
Upgrade Alert for Impax Laboratories (IPXL)
Comtex SmarTrend(R) - Tue Aug 16, 3:03AM CDT
Impax Laboratories (NASDAQ:IPXL) was upgraded from Market Perform to Outperform at Northland today. The stock closed yesterday at $22.97 on volume of 1.4 million shares, above average daily volume of 539,000. In the past 52 weeks, Impax Laboratories share prices have been bracketed by a low of $20.97 and a high of $52.10 and closed yesterday at $22.97, 10% above that low price. The 200-day and 50-day moving averages have moved 0.87% lower and 0.04% lower over the past week, respectively.
IPXL: 24.03 (+0.09)
Impax Laboratories Has Returned 23.0% Since SmarTrend Recommendation (IPXL)
Comtex SmarTrend(R) - Thu Aug 11, 1:35PM CDT
SmarTrend identified a Downtrend for Impax Laboratories (NASDAQ:IPXL) on June 21st, 2016 at $28.86. In approximately 2 months, Impax Laboratories has returned 22.97% as of today's recent price of $22.23.
IPXL: 24.03 (+0.09)
5 Low Price-to-Book Stocks That Can Prove Valuable
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 7:13AM CDT
The price-to-book ratio (P/B ratio), though underrated, is also an easy-to-use valuation tool for identifying low-priced stocks with high-growth prospects.
IPXL: 24.03 (+0.09), KEP: 25.87 (+0.11), NTT: 45.31 (+0.83), HZNP: 17.84 (-0.78), DF: 17.25 (+0.20)
Valeant, Endo and Monster Worldwide surge; Gap slackens
AP - Tue Aug 09, 4:37PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
IPXL: 24.03 (+0.09), ENDP: 19.82 (-0.41), VRX: 28.76 (-0.36), DAL: 37.17 (+0.35), MWW: 3.72 (+0.05), MPAA: 29.06 (+0.39), GPS: 23.92 (-0.63), SNI: 63.83 (+0.25), VRX.TO: 37.34 (-0.75)
Impax Laboratories Falls 23.19% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 09, 1:07PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $22.08 to a high of $25.05. Yesterday, the shares fell 23.2%, which took the trading range below the 3-day low of $30.44 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IPXL: 24.03 (+0.09)
After Yesterday's Decline of 23.19%, Impax Laboratories Offers Investors Better Value
Comtex SmarTrend(R) - Tue Aug 09, 1:06PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $22.08 to a high of $25.05. Yesterday, the shares fell 23.2%, which took the trading range below the 3-day low of $30.44 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IPXL: 24.03 (+0.09)
Zacks.com featured highlights: Dean Foods, Korea Electric Power, Impax Laboratories, Xerox and AerCap Holdings N.V.
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:30AM CDT
Zacks.com featured highlights: Dean Foods, Korea Electric Power, Impax Laboratories, Xerox and AerCap Holdings N.V.
IPXL: 24.03 (+0.09), AER: 40.57 (+0.43), KEP: 25.87 (+0.11), XRX: 9.89 (+0.02), DF: 17.25 (+0.20)
Impax Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported second quarter 2016 financial results for the quarter ended June 30, 2016.
IPXL: 24.03 (+0.09)
5 Stocks with Low Price-to-Cash-Flow Ratio to Buy Now
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 6:35AM CDT
Investment in stocks made on diligent value analysis is usually considered one of the best practices.
IPXL: 24.03 (+0.09), AER: 40.57 (+0.43), KEP: 25.87 (+0.11), XRX: 9.89 (+0.02), DF: 17.25 (+0.20)
Mylan (MYL) Q2 Earnings: Will the Stock Disappoint?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 3:15PM CDT
Mylan (MYL), which is set to report second-quarter 2016 results on Aug 9, delivered a positive earnings surprise of 1.33% last quarter.
IPXL: 24.03 (+0.09), INCY: 82.02 (+1.21), MYL: 39.97 (-1.95), IONS: 29.46 (-0.58)
Tessera (TSRA) Surpasses Q2 Earnings & Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 2:18PM CDT
Tessera's djusted earnings of 55 cents per share surpassed the Zacks Consensus Estimate by 7.8% or 4 cents. Revenues of $67 million beat the consensus mark of $65 million by 3.1%.
IPXL: 24.03 (+0.09), TSRA: 33.79 (+0.08), MEET: 5.90 (+0.03), MYL: 39.97 (-1.95)
Monster Worldwide (MWW) Q2 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:42AM CDT
Monster Worldwide, Inc. (MWW) is set to report second-quarter 2016 results on Aug 9.
IPXL: 24.03 (+0.09), LNKD: 192.80 (+0.07), MWW: 3.72 (+0.05), MYL: 39.97 (-1.95)
BioDelivery (BDSI) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 6:58AM CDT
Last quarter, BioDelivery's loss was in-line with expectations. Let's see how things are shaping up for the second quarter of 2016.
IPXL: 24.03 (+0.09), BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), INCY: 82.02 (+1.21)
Jazz (JAZZ) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 6:45AM CDT
Our proven model does not conclusively show that Jazz (JAZZ) is likely to beat earnings estimates this quarter.
IPXL: 24.03 (+0.09), ADHD: 4.77 (+0.03), JAZZ: 120.84 (-2.47), INCY: 82.02 (+1.21)
Immune Design (IMDZ): Stock to Disappoint on Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 5:23PM CDT
Immune Design Corp. (IMDZ) is scheduled to report second-quarter 2016 results after the market closes on Aug 9.
IPXL: 24.03 (+0.09), IMDZ: 7.07 (-0.04), MRK: 62.98 (+0.08)
Will Endo (ENDP) Surprise This Earnings Season Again?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 5:22PM CDT
Endo International (ENDP) is set to report second-quarter 2016 results on Aug 8. It posted a positive earnings surprise of 2.86% last quarter.
IPXL: 24.03 (+0.09), ENDP: 19.82 (-0.41), MYL: 39.97 (-1.95), IONS: 29.46 (-0.58)
